Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 73 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Atorvastatin 80 mg Clear all
Completed Phase 3 Interventional Results available

CRESTOR Athero Imaging Head to Head IVUS Study

NCT00620542
View directory record Official record
Conditions
Coronary Atherosclerosis
Interventions
Rosuvastatin, Atorvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
2,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
97
States / cities
Huntsville, Alabama • Los Angeles, California • Mountain View, California + 94 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 3 Interventional Results available

Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)

NCT01528709
View directory record Official record
Conditions
Saphenous Vein Graft Disease
Interventions
Atorvastatin 80 mg daily, Atorvastatin 10 mg daily
Drug
Lead sponsor
Boca Raton Regional Hospital
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bioavailability Study for New Atorvastatin Formulation

NCT00844376
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin suspension, Lipitor
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 7, 2026, 10:48 AM EDT
Withdrawn Not applicable Interventional

Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery

NCT01186289
View directory record Official record
Conditions
Neurocognitive Dysfunction
Interventions
atorvastatin
Drug
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 7, 2026, 10:48 AM EDT
Recruiting Phase 2 Interventional

Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)

NCT05483010
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance, Myelodysplastic Syndromes
Interventions
Atorvastatin, Rosuvastatin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 7, 2026, 10:48 AM EDT
Not listed Phase 4 Interventional

Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF)

NCT02029534
View directory record Official record
Conditions
Cardiothoracic Surgery, Post-operative Atrial Fibrillation
Interventions
Atorvastatin 20 mg, Atorvastatin 80 mg
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet

NCT00917644
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin, Atorvastatin
Drug · Genetic
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

NCT01730040
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
56
States / cities
Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 3 Interventional Results available

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

NCT01763866
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe, Atorvastatin, Rosuvastatin, Simvastatin
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
65
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 4 Interventional Results available

The Use of Statins Following a Left Atrial Catheter Ablation Procedure to Prevent Atrial Fibrillation

NCT00579098
View directory record Official record
Conditions
Atrial Fibrillation, Arrhythmia, Inflammation, Endothelial Dysfunction
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CHOlesterol Lowering and Residual Risk in Type 2 Diabetes

NCT04369664
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Statin, PCSK9 inhibitor, Ezetimibe 10mg
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 89 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial

NCT02603328
View directory record Official record
Conditions
Cerebral Cavernous Malformation
Interventions
Atorvastatin, Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Statin Medications on Muscle Performance (The STOMP Study)

NCT00609063
View directory record Official record
Conditions
Hydroxymethylglutaryl-CoA Reductase Inhibitors, Muscular Diseases
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
20 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
Hartford, Connecticut • Storrs, Connecticut • Amherst, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2012 · Synced Oct 7, 2026, 10:48 AM EDT
Active, not recruiting Phase 4 Interventional

Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

NCT03417388
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily, Lifestyle Counseling, Quality of Life Questionnaires
Drug · Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
2,476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
80
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 4 Interventional

Do HMG CoA Reductase Inhibitors Affect Abeta Levels?

NCT00303277
View directory record Official record
Conditions
Alzheimer's Disease, Aging
Interventions
simvastatin, pravastatin
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 90 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 13, 2010 · Synced Oct 7, 2026, 10:48 AM EDT
Terminated Phase 2 Interventional Results available

Mission Connect Mild Traumatic Brain Injury (TBI) Integrated Clinical Protocol

NCT01013870
View directory record Official record
Conditions
Traumatic Brain Injury, Post-traumatic Stress Disorder
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Early Phase 1 Interventional

A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium

NCT02767362
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Atorvastatin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 3 Interventional

To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.

NCT00151502
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Atorvastatin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
40
States / cities
Sun City, Arizona • Fresno, California • Laguna Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy

NCT05342974
View directory record Official record
Conditions
Abortion Early
Interventions
Atorvastatin, Misoprostol
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 7, 2026, 10:48 AM EDT
Terminated Phase 3 Interventional Results available

Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)

NCT00252967
View directory record Official record
Conditions
Atrial Fibrillation, Inflammation
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 2 Interventional Results available

Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells

NCT00166036
View directory record Official record
Conditions
Diabetes Mellitus, Metabolic Syndrome X, Hypercholesterolemia
Interventions
Atorvastatin, Pravastatin
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 7, 2026, 10:48 AM EDT
Terminated Early Phase 1 Interventional

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

NCT03507374
View directory record Official record
Conditions
Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 3 Interventional Results available

Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

NCT00300469
View directory record Official record
Conditions
Mixed Dyslipidemia, Coronary Heart Disease, Dyslipidemia
Interventions
ABT-335, Atorvastatin, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 7, 2026, 10:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Of Pediatric Appropriate Formulation

NCT00758004
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin, Atorvastatin pediatric appropriate formulation
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 7, 2026, 10:48 AM EDT